{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-018481","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.659959+00:00","generated_at":"2026-06-14T18:16:13.735723+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BriaCell closes $4M strategic investment by Prevail Partners at $8.63/share","bullets":["Issued 463,408 common shares to Prevail Partners for aggregate gross proceeds of $4 million.","Price per share was US$8.63; TSX approved the transaction on May 18, 2023.","Proceeds to fund CRO clinical services and technologies for upcoming pivotal study in advanced metastatic breast cancer.","Shares subject to four-month-and-one-day hold period under Canadian securities laws.","Prevail Partners' affiliate, Prevail InfoWorks, will provide clinical services and real-time data analytics platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-018481","json":"https://secwatch.observer/filing/0001493152-23-018481.json","markdown":"https://secwatch.observer/filing/0001493152-23-018481.md","text":"https://secwatch.observer/filing/0001493152-23-018481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223018481/0001493152-23-018481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223018481/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:16:13.735723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}